3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
46
Neoplasm Metastasis
5
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Bulbo-Spinal Atrophy, X-Linked
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Interventions
Specimen Handling
7
Biopsy
6
Cyclophosphamide
5
ruxolitinib
4
Mycophenolic Acid
4
Busulfan
4
fludarabine phosphate
3
fludarabine
3
Whole-Body Irradiation
3
Tacrolimus
3
Melphalan
3
Injections
3
Decitabine
3
Cyclosporine
3
Azacitidine
3
venetoclax
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Methotrexate
2
Granulocyte Colony-Stimulating Factor
2
veliparib
1
tocilizumab
1
tagraxofusp
1
posaconazole
1
peginterferon alfa-2b
1
onvansertib
1
merphos
1
iadademstat
1
gilteritinib
1
fedratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
abiraterone
×
1 year
×
Clear all
No trials found.